The Gut Microbiome in Women With Polycystic Ovary Syndrome

NCT03642600 on ClinicalTrials.gov · last registry update 2020-11-04

A small phase 4 — 21 participants, against a typical 75. The sponsor logged completion for 1 February 2020. Primary outcome, as filed: weight loss. liraglutide is approved in the US, but not for metabolic syndrome and pcos — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: COMPLETED
Phase: P4
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Universitaire Ziekenhuizen KU Leuven
Sponsor type: Other
Enrollment: 21
Started: 2019-02-28
Primary completion: 2020-02-01 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

weight loss

Conditions studied

PCOS · Obesity · Metabolic Syndrome

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.